pharmacokinetic profile, therefore, it was not developed further. In order to enrich the structural types of urea-based TRPV1 antagonists, two series of novel analogs, in which the pyridine ring of BCTC was replaced with a mildly basic pyrimidine ring or 1,2,3,4-tetrahydro-β-carboline scaffold, were designed and synthesized. Advancing the structure-activity relationship of these two series led to the discovery of
N-(4-
叔丁基苯基)-4-(3-
氯吡啶-2-基)
哌嗪-1-羧酰胺(BCTC)是一种有效且经过广泛研究的基于
尿素的TRPV1拮抗剂。尽管BCTC可以有效减轻大鼠的慢性疼痛,但它显示出明显的高热副作用和不理想的药代动力学特征,因此没有进一步发展。为了丰富基于
尿素的TRPV1拮抗剂的结构类型,使用了两个新的类似物系列,其中BCTC的
吡啶环被温和的碱性
嘧啶环或1,2,3,4-四氢-β-咔啉骨架取代,进行了设计和合成。推进这两个系列的结构-活性关系导致发现N-(4-
甲氧基苯基)-1,3,4,9-四氢-2 H-
吡啶基[3,4- b] indole-2-carboxamide(7o),与先导化合物BCTC相比,具有改善的药理和耐受性。